Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA adverse Event Reporting System (FAERS)

CONCLUSION: Analysis of FAERS data identified anti-IL-5 mAbs-associated AEs, and our findings supported continuous clinical monitoring, pharmacovigilance, and further studies of anti-IL-5 mAbs. In addition, clinicians may be more aware of the limitations of use in package inserts of anti-IL-5 mAbs: Not for relief of acute bronchospasm or status asthmaticus. Because of some limitations in the FAERS such as self-reports from patients and other confounding factors, the safety of anti-IL-5 mAbs needed more studies in different dimensions, especially the risk of cancer.PMID:37610085 | DOI:10.1080/14740338.2023.2251382
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Source Type: research